Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
Authors' conclusion
Lenvatinib is an effective treatment for real-world PDTC patients. Adequate management of comorbidities and AEs increases treatment tolerability and minimizes dose reductions.
Study context
- Population
- Consecutive patients with PDTC (Turin criteria) with disease progression in the previous 6 months, treated with lenvatinib at a single centre, January 2019–October 2022; ECOG performance status ≥2 in 50%
- Participants
- 8 patients
- Outcome
- Effectiveness: disease control rate and best response
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
- Disease control rate
- 100%
- Partial response
- 12.5%
- Stable disease
- 87.5%
- Median time to best overall response
- 3 months
- Median duration of response
- 7.5 months
- Median PFS
- 12 months
- Median overall survival
- not reached
Observational data: associations, not effects.
Further findings
Response timing
Months
- Median time to best overall response
- 3
- Median duration of response
- 7.5
PFS and OS
- Median PFS
- 12 months
- Median OS
- not reached
- OS at 6 months
- 87.5%
- OS at 12 months
- 71.4%
- OS at 18 months
- 57.1%
Safety
- Drug-related adverse effects (AEs)
- all patients
- Dose reductions
- 4 (50%)
- Temporary treatment interruptions
- 2 (25%)
- Lenvatinib stopped due to grade ≥3 AEs
- 2 patients
Original publication
Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma. Eur Thyroid J. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →